Lillie D. Shockney RN, BS, MAS, HON-ONN-CG
University Distinguished Service Professor of Breast Cancer, Professor of Surgery, Johns Hopkins University School of Medicine; Co-Founder, Academy of Oncology Nurse & Patient Navigators; Co-Developer, Work Stride — Managing Cancer at Work, Johns Hopkins Healthcare Solutions, Baltimore, MarylandProf. Lillie D. Shockney, a specialist in the care of patients with breast cancer, is well-known in the cancer field, especially the areas of navigation, survivorship, patient-centered care, preservation of quality of life, end-of-life planning and care, improving the cancer patient’s experience, and clinical outcomes. Her research focuses on the preservation of quality of life for patients with metastatic breast cancer.
In 2016, Prof. Shockney was promoted to full professor, and she is the only nurse at Johns Hopkins to have a primary faculty appointment in the School of Medicine and the only nurse in the country to have reached the highest academic faculty ranking and be appointed to a faculty chair as a University Distinguished Service Professor of Breast Cancer at Johns Hopkins University School of Medicine.
Prof. Shockney is the co-founder of the Academy of Oncology Nurse & Patient Navigators (AONN+), a national professional organization for those working in the navigation space with oncology patients, which has more than 9000 members. She has served as a consultant for breast cancer for ABC News and Good Morning America and has been consulted regularly by the Today Show and CNN. She currently serves on 28 medical advisory boards. She has authored 30 books and more than 350 articles on breast cancer and on topics such as oncology navigation, survivorship, and patient advocacy. She has received 62 awards — 54 national awards, 7 state awards, and 1 international award, and several national lifetime achievement awards.
Disclosures
- Speakers bureau for Pfizer Oncology
Recent Contributions to PracticeUpdate:
- 2024 Top Story in Metastatic Breast Cancer: Epidemiology of Early vs Late Recurrence Among Women With Early-Stage ER+ Breast Cancer
- Real-World Evidence on Prescribing Patterns and Clinical Outcomes in Patients With MBC Treated With PARP Inhibitors
- Intracranial Outcomes Following Neurosurgical Resection in Patients With Brain Metastases Secondary to HER2+ Breast Cancer vs Other Subtypes
- Integrative Multiomic Profiling of TNBC for Identifying Suitable Therapies
- Real-World Effectiveness of Palbociclib Plus Endocrine Therapy in HR+/HER2− Advanced Breast Cancer
- Efficacy and Safety of Trastuzumab Deruxtecan Plus Nivolumab in Patients With HER2-Expressing Metastatic Breast or Urothelial Cancer
- Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Treatment Failure in ER+ Metastatic Breast Cancer
- Outcomes and Prognostic Factors Associated With Brain Metastasis in Triple-Negative Breast Cancer
- Pharmacokinetics and Pharmacogenomics of Ribociclib in Black Patients With Metastatic Breast Cancer
- Acquired Gene Alterations in Patients Treated With Endocrine Therapy ± Ribociclib Using Baseline and End-of-Treatment ctDNA Samples